Mandate

Vinge advises Stendörren in connection with issuance of green capital securities and tender offer

May 17, 2024 Banking and Finance

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green subordinated and perpetual capital securities in an amount of SEK 300 million (within a framework of SEK 400 million) and its parallel tender offer in respect of its previously issued capital securities.

The capital securities were issued with a coupon of STIBOR 3m + 550 basis points until the first ordinary call date, and they are intended to be listed on the sustainable bond list of Nasdaq Stockholm. An amount equivalent to the net proceeds from the issuance will be applied in accordance with Stendörren’s green finance framework and towards the repurchase of its outstanding capital securities. Stendörren has received tenders in a total nominal amount of SEK 132,500,000 and intends to accept all tenders received.

Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) acted as arrangers and joint bookrunners in connection with the issuance of the green capital securities, and as dealer managers in connection with the tender offer.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda and Calle Tengwall Pagels.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025